Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema

Immunology and Allergy Clinics of North America

Volumn 26, Issue 4, 2006, Pages 725-737

  Byrd, James Brian ^a   Adam, Albert ^b   Brown, Nancy J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMINOPEPTIDASE P; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHISTAMINIC AGENT; BRADYKININ ANTAGONIST; BRADYKININ B2 RECEPTOR ANTAGONIST; CAPTOPRIL; COMPLEMENT COMPONENT C1S INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV; ENALAPRIL; FRESH FROZEN PLASMA; ICATIBANT; NEUROKININ 1 RECEPTOR ANTAGONIST; OMAPATRILAT; STEROID; TACHYKININ; VASOACTIVE AGENT;

ABDOMINAL PAIN; AFRICAN AMERICAN; ANGIONEUROTIC EDEMA; ASCITES; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DEGRADATION; DIARRHEA; DRUG MECHANISM; EARLY DIAGNOSIS; ENZYME ACTIVITY; EUROPEAN AMERICAN; FACE EDEMA; HUMAN; IMMUNOPATHOGENESIS; LIP EDEMA; NAUSEA AND VOMITING; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; RACE DIFFERENCE; RECURRENT DISEASE; REVIEW; RISK FACTOR; SMOKING; STROKE; TONGUE EDEMA; TREATMENT DURATION; VASODILATATION;

ANGIONEUROTIC EDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PEDIGREE;

EID: 33750583287     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2006.08.001     Document Type: Review

References (49)

1. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
2. Lewis E.J., Hunsicker L.G., Bain R.P., et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329 (1993) 1456-1462
3. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 3 (2000) 145-153
4. Dahlof B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 9489 (2005) 895-906
5. Agah R., Bandi V., and Guntupalli K.K. Angioedema: the role of ACE inhibitors and factors associated with poor clinical outcome. Intensive Care Med 23 7 (1997) 793-796
6. Cicardi M., Zingale L.C., Bergamaschini L., et al. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med 164 8 (2004) 910-913
7. Kostis J.B., Kim H.J., Rusnak J., et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med 165 14 (2005) 1637-1642
8. Schmidt T.D., and McGrath K.M. Angiotensin-converting enzyme inhibitor angioedema of the intestine: a case report and review of the literature. Am J Med Sci 324 2 (2002) 106-108
9. Hill M.D., and Buchan A.M. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 172 10 (2005) 1307-1312
10. Slater E.E., Merrill D.D., Guess H.A., et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 260 7 (1988) 967-970
11. Gabb G.M., Ryan P., Wing L.M., et al. Epidemiological study of angioedema and ACE inhibitors. Aust N Z J Med 26 6 (1996) 777-782
12. Brown N.J., Ray W.A., Snowden M., et al. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 60 1 (1996) 8-13
13. Agostoni A., Cicardi M., Cugno M., et al. Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology 44 1-2 (1999) 21-25
14. Nielsen E.W., and Gramstad S. Angioedema from angiotensin-converting enzyme (ACE) inhibitor treated with complement 1 (C1) inhibitor concentrate. Acta Anaesthesiol Scand 50 1 (2006) 120-122
15. Warrier M.R., Copilevitz C.A., Dykewicz M.S., et al. Fresh frozen plasma in the treatment of resistant angiotensin-converting enzyme inhibitor angioedema. Ann Allergy Asthma Immunol 92 5 (2004) 573-575
16. Icatibant. HOE 140, JE 049, JE049. Drugs R D 5 6 (2004) 343-348
17. Cockcroft J.R., Sciberras D.G., Goldberg M.R., et al. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J Cardiovasc Pharmacol 22 4 (1993) 579-584
18. Carey R.M., Wang Z.Q., and Siragy H.M. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 35 1 Pt 2 (2000) 155-163 [Review. 92 refs.]
19. Campbell D.J., Krum H., and Esler M.D. Losartan increases bradykinin levels in hypertensive humans. Circulation 111 3 (2005) 315-320
20. Johnsen S.P., Jacobsen J., Monster T.B., et al. Risk of first-time hospitalization for angioedema among users of ACE inhibitors and angiotensin receptor antagonists. Am J Med 118 12 (2005) 1428-1429
21. Sica D.A. The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned?. J Clin Hypertens (Greenwich) 5 2 (2003) 159-167
22. Kostis J.B., Packer M., Black H.R., et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 17 2 (2004) 103-111
23. Gibbs C.R., Lip G.Y., and Beevers D.G. Angioedema due to ACE inhibitors: increased risk in patients of African origin. Br J Clin Pharmacol 48 6 (1999) 861-865 [see comments]
24. Morimoto T., Gandhi T.K., Fiskio J.M., et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 10 4 (2004) 499-509
25. Woo K.S., Norris R.M., and Nicholls G. Racial difference in incidence of cough with angiotensin-converting enzyme inhibitors (a tale of two cities). Am J Cardiol 75 14 (1995) 967-968
26. Abbosh J., Anderson J.A., Levine A.B., et al. Angiotensin converting enzyme inhibitor-induced angioedema more prevalent in transplant patients. Ann Allergy Asthma Immunol 82 5 (1999) 473-476
27. Brown N.J., Snowden M., and Griffin M.R. Recurrent angiotensin-converting enzyme inhibitor-associated angioedema. JAMA 278 3 (1997) 232-233
28. Gainer J.V., Morrow J.D., Loveland A., et al. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 339 18 (1998) 1285-1292
29. Schapira M., Silver L.D., Scott C.F., et al. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med 308 (1983) 1050-1054
30. Han E.D., MacFarlane R.C., Mulligan A.N., et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 109 8 (2002) 1057-1063
31. Moreau M.E., Dubreuil P., Molinaro G., et al. Expression of metallopeptidases and kinin receptors in swine oropharyngeal tissues: effects of angiotensin I-converting enzyme inhibition and inflammation. J Pharmacol Exp Ther 315 3 (2005) 1065-1074
32. Nussberger J., Cugno M., Amstutz C., et al. Plasma bradykinin in angio-oedema. Lancet 351 9117 (1998) 1693-1697
33. Molinaro G., Cugno M., Perez M., et al. Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin. J Pharmacol Exp Ther 303 1 (2002) 232-237
34. Emanueli C., Grady E.F., Madeddu P., et al. Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P. Hypertension 31 6 (1998) 1299-1304
35. Sulpizio A.C., Pullen M.A., Edwards R.M., et al. The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat. J Pharmacol Exp Ther 309 3 (2004) 1141-1147
36. Kopp U.C., Farley D.M., and Smith L.A. Bradykinin-mediated activation of renal sensory neurons due to prostaglandin-dependent release of substance P. Am J Physiol 272 6 Pt 2 (1997) R2009-R2016
37. Campos M.M., and Calixto J.B. Neurokinin mediation of edema and inflammation. Neuropeptides 34 5 (2000) 314-322
38. Moreau M.E., Garbacki N., Molinaro G., et al. The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci 99 1 (2005) 6-38
39. Blais C.J., Rouleau J.L., Brown N.J., et al. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology 43 2-3 (1999) 293-302
40. Ersahin C., and Simmons W.H. Inhibition of both aminopeptidase P and angiotensin-converting enzyme prevents bradykinin degradation in the rat coronary circulation. J Cardiovasc Pharmacol 30 1 (1997) 96-101
41. Kim K.S., Kumar S., Simmons W.H., et al. Inhibition of aminopeptidase P potentiates wheal response to bradykinin in angiotensin-converting enzyme inhibitor-treated humans. J Pharmacol Exp Ther 292 1 (2000) 295-298
42. Adam A., Cugno M., Molinaro G., et al. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet 359 9323 (2002) 2088-2089
43. Cyr M., Lepage Y., Blais Jr. C., et al. Bradykinin and des-Arg(9)-bradykinin metabolic pathways and kinetics of activation of human plasma. Am J Physiol Heart Circ Physiol 281 1 (2001) H275-H283
44. Duan Q.L., Nikpoor B., Dube M.P., et al. A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am J Hum Genet 77 4 (2005) 617-626
45. Russell J.S., Chi H., Lantry L.E., et al. Substance P and neurokinin A metabolism by cultured human skeletal muscle myocytes and fibroblasts. Peptides 17 8 (1996) 1397-1403
46. Lefebvre J., Murphey L.J., Hartert T.V., et al. Dipeptidyly peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension 39 (2002) 460-464
47. Sprinkle T.J., Stone A.A., Venema R.C., et al. Assignment of the membrane-bound human aminopeptidase P gene (XPNPEP2) to chromosome Xq25. Genomics 50 1 (1998) 114-116
48. Sprinkle T.J., Caldwell C., and Ryan J.W. Cloning, chromosomal sublocalization of the human soluble aminopeptidase P gene (XPNPEP1) to 10q25.3 and conservation of the putative proton shuttle and metal ligand binding sites with XPNPEP2. Arch Biochem Biophys 378 1 (2000) 51-56
49. Abbott C.A., Baker E., Sutherland G.R., et al. Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene. Immunogenetics 40 5 (1994) 331-338